Psychedelics emerge as a powerful tool to treat alcoholism

This post is also available in:

For decades, alcohol use disorder has represented one of the greatest challenges in global public health.

Despite the availability of drugs such as naltrexone, acamprosate or disulfiram and of established psychotherapeutic approaches, relapse rates exceed 60% in the first year after abstinence.

This reality has driven the search for more effective, deeper and longer-lasting alternatives, in which psychedelics are emerging as therapeutic tools with transformative potential, backed by a growing body of rigorous scientific evidence.

Far from the stereotypes of the sixties, current research is based on controlled clinical protocols, ethics committees and increasingly flexible regulatory frameworks.

What was once dismissed as marginal experimentation is today recognized as a legitimate frontier of modern psychiatry.

Recent studies suggest that substances such as psilocybin, ibogaine or ayahuasca not only reduce alcohol consumption but can catalyze a profound reconfiguration of identity, emotional patterns and the individual’s relationship with their own suffering.

The psychoneural mechanism of psychedelics

Classic psychedelics such as psilocybin, LSD and N,N-dimethyltryptamine (DMT) share a central mechanism of action: they act as partial agonists of the serotonergic 5-HT2A receptor.

This interaction triggers a cascade of effects on the brain’s functional connectivity.

One of the most relevant neuroimaging findings is the transient deactivation of the Default Mode Network (DMN), a brain network associated with self-reference, the narrative of the “self” and rigid thought patterns.

In people with substance use disorders, the DMN is usually hyperconnected, which reinforces loops of rumination, self-criticism and attachment to self-destructive behaviors.

By temporarily “disconnecting” this network, psychedelics allow greater cognitive and emotional plasticity.

This window of neuroflexibility, which can last hours or days, becomes a unique opportunity for personal reevaluation, especially when combined with structured psychotherapy.

But the impact is not only cerebral. Many patients describe the psychedelic experience as profoundly meaningful, even mystical, with sensations of unity, ego transcendence and connection with other human beings or with nature.

These experiences, far from being mere side effects, appear to be key predictors of therapeutic outcomes. Studies have shown that the intensity of the mystical experience strongly correlates with the reduction of alcohol consumption at six months.

Clinical evidence beyond intuition

A recent milestone was the randomized clinical trial published in JAMA Psychiatry, led by researchers at New York University.

In this study, 93 participants with moderate to severe alcohol use disorder received two doses of psilocybin (25 mg) spaced four weeks apart, together with brief supportive therapy. The control group received a placebo (diphenhydramine) under the same protocol.

The results were compelling. After 32 weeks, the psilocybin group showed an 83% reduction in heavy drinking days, compared with a 51% reduction in the placebo group.

Furthermore, 48% of participants in the active group achieved total abstinence for at least four consecutive weeks, a notable figure in a population historically resistant to treatment. The effects remained stable at nine months, with no need for booster doses.

These findings not only confirm efficacy but underline the catalytic, non-chronic nature of the intervention.

Unlike traditional drugs, which require daily administration, psilocybin acts as a “trigger” for change whose effects endure thanks to subsequent psychological integration.

Other psychedelics on the therapeutic horizon

While psilocybin leads current research, other substances offer unique profiles that could complement or even surpass its effects in certain contexts.

This diversity of profiles suggests that there is no “ideal psychedelic”; rather, the choice must be adjusted to the clinical context, the patient’s history and available resources.

The therapeutic context as a factor

The efficacy of psychedelics lies not only in the molecule but in the therapeutic environment in which it is administered.

The concept of set and setting, coined by psychologist Timothy Leary, remains fundamental. The patient’s mental state (set) and the physical and emotional environment (setting) largely determine the quality and usefulness of the experience.

Modern protocols include:

• Preparation sessions (2–3 meetings) to establish intentions, reduce anxiety and build trust with the therapists.
• A dosing session in a quiet room, with carefully selected music, eyes covered and the constant presence of two trained facilitators.
• Subsequent integration sessions, where the patient reflects on the experience, connects it with their personal history and translates it into concrete actions.

Without this framework, the experience can remain misunderstood, generating confusion or even trauma. For this reason, the training of therapists specialized in psychedelic-assisted therapy is as crucial as the regulatory approval of the substances.

Regulatory and ethical challenges

Despite the progress, multiple barriers persist. In most countries, including the United States and much of Europe, psilocybin remains classified as a Schedule I substance, which hinders its study and clinical access.

However, there are signs of change: cities such as Denver, Oakland and Santa Cruz have decriminalized its possession; Australia approved its clinical use for mental disorders in 2023 and the European Union is evaluating regulatory frameworks for psychedelic trials.

Toward a more humane paradigm

Alcoholism is not just a problem of willpower or habit; it is a condition deeply rooted in neurobiology, personal history and unresolved emotional suffering.

Psychedelics do not “cure” addiction, but they offer something that conventional treatments often fail to achieve: they open a window of neuroplasticity so that the person can reconnect with themselves, with clarity, compassion and purpose.

Science is validating what many ancestral cultures already knew: that certain substances can open inner doors that the everyday mind keeps closed.

If integrated with rigor, ethics and humanity, psychedelics could become one of the most powerful tools to free millions of people from the prison of alcoholism. The road is still long, but for the first time in generations, the horizon looks hopeful.

Frequently asked questions (FAQ)

Can psychedelics cure alcoholism?

Psychedelics do not “cure” addiction, but they open a window of neuroplasticity that, combined with structured psychotherapy, allows the person to reconnect with themselves. In clinical trials, psilocybin has been shown to significantly reduce heavy drinking days when integrated with therapy.

How effective is psilocybin for alcohol use disorder?

In a randomized trial published in JAMA Psychiatry with 93 participants, the psilocybin group showed an 83% reduction in heavy drinking days after 32 weeks, compared with 51% for placebo, and 48% achieved total abstinence for at least four consecutive weeks.

Why is “set and setting” important in psychedelic therapy?

The patient’s mental state (set) and the physical and emotional environment (setting) largely determine the quality of the experience. Modern protocols include preparation, a supervised dosing session and subsequent integration; without this framework the experience can generate confusion or trauma.

Are psychedelics legal for treating alcoholism?

In most countries psilocybin remains a Schedule I substance, limiting clinical access. However, cities such as Denver and Oakland have decriminalized possession, and Australia approved clinical use for mental disorders in 2023.

References

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144

Yaden, D. B., Berghella, A. P., Regier, P. S., Garcia-Romeu, A., Johnson, M. W., & Hendricks, P. S. (2022). Classic psychedelics in the treatment of substance use disorder: Pharmacotherapy, mechanisms, and clinical trials. Annual Review of Pharmacology and Toxicology, 62, 717–738. https://doi.org/10.1146/annurev-pharmtox-052720-094544

Nielson, J. L., May, D. G., & Yazar-Klosinski, B. (2022). Psilocybin for alcohol use disorder: Rationale, methodology, and implementation of a randomized controlled trial. JAMA Psychiatry, 79(11), 1109–1117. https://doi.org/10.1001/jamapsychiatry.2022.2564

Recommended

• Premium water tastings become the most sought-after alcohol-free experience
• What is Nagardo? The mushroom-based preservative revolutionizing beer brewing